Discovery is in our nature
Introducing a new generation of psychedelic-inspired medicines
We have created a vast library of patentable and highly active new chemical entities (NCEs) that are designed to target serotonin receptors in a specific manner to enable the treatment of multiple neurological diseases and disorders.
PsiloSterics | Who We Are
Moving beyond the First-Gen approach
First-generation psychedelic companies are largely focused on “repackaging” old drugs that were initially discovered by scientists more than 30 years ago, resulting in many companies pursuing the advancement of known hallucinogenic drugs that require the presence of a medical professional when administered to patients.
Our next-gen approach: Pseudo-psychedelic therapeutics
We have designed and synthesized novel, non-hallucinogenic serotonin receptor agonists that reduce or eliminate the cardiotoxic effects commonly observed with known hallucinogenic drugs, allowing for long-term, unsupervised administration to patients on a daily or weekly basis. This design approach has guided us to over a dozen proprietary, patent-pending molecular scaffolds covering thousands of novel therapeutic compounds that can be tailored to target a variety of neurological disorders.
Collaborating with some of the top academic groups in the industry, our top NCE candidates are being advanced through a battery of in vitro and in vivo pre-clinical studies to enable lead candidate selection and optimization.
a New Generation of psychedelic inspired medicines
By combining proprietary SAR analytics, medicinal chemistry analyses, and exhaustive prior art research, we design and synthesize novel molecular scaffolds.
Using in silico screening and molecular modeling, we narrow our focus to refine and select scaffolds with the highest likelihood of replicating – or exceeding – the therapeutic benefits of traditional psychedelic compounds, while reducing or eliminating the hallucinogenic and cardiotoxic aspects of those drugs.
We rigorously examine the IP landscape to determine patentability and freedom to operate for our novel scaffolds and their related NCE candidates. So far, this has resulted in the preparation and filing of more than 30 patent applications, with many of those applications individually disclosing 500+ novel compounds.
Leveraging our in-house laboratory and 50+ years of combined medicinal chemistry expertise, we synthesize, prepare and characterize our NCEs for in vitro and in vivo studies.
Once identified as a potential lead, our top NCE candidates are advanced into our pre-clinical program with leading academic collaborators for optimization and indication-specific studies.
The Opportunity Ahead
Psychedelic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. However, many First-Gen natural and synthetic analogs are not optimized for continual therapeutic use. Our novel therapeutics are designed without the hallucinogenic and other side effects that have prevented existing psychedelics from being widely adopted for addressing the current global epidemic of mental health disorders.
Unlike naturally-occurring or synthetic serotonergic agents previously developed, our new generation of NCEs are novel and patentable, allowing us to avoid the vast and complicated IP landscape created by First-Gen companies. PsiloSterics exclusively owns all intellectual property rights associated with its proprietary scaffolds and NCEs.
Previously, Allen served as the Chairman and Chief Executive Officer of BioSynthetic Technologies, a specialty chemical company that created novel, bio-based synthetic compounds having a variety of applications in the industrial, personal care, and pharmaceutical sectors. While at BioSynthetic, Allen raised $65 million from venture partners including BP, Monsanto and Evonik Industries. Allen led a talented team of chemists that invented, scale-manufactured, and contract-validated dozens of new compounds, which led to the issuance of more than 150 patents. Prior to that, Mr. Barbieri served as Chief Executive Officer of Lancer Orthodontics, Inc., a manufacturer of orthodontic devices with operations in Mexico and San Diego. Before this, Allen served as President and Chief Financial Officer of BUY.COM, a large internet retailer financed with over $300 million in venture capital from Soft Bank. Allen has also served as the President and Chief Executive Officer of Pacific National Bank, President of Capital Bancorp, a commercial bank holding company, Chief Financial Officer of First Federal Bank, and as an Investment Banking Associate of Merrill Lynch Capital Markets in New York.
Allen holds an M.B.A. Degree from the MIT - Sloan School of Management, and a Bachelor’s Degree in Finance from Brigham Young University.
David also brings a wealth of expertise in designing, synthesizing, and characterizing psychoactive drugs. He spent nearly 10 years as a student and graduate researcher at the University of Hawaii creating novel cannabinoid analogs, prodrugs and targeted covalent inhibitors. Notably, his research played a key role in the elucidation of the cannabinoid receptor binding pocket and the first crystal structure of Cannabinoid Receptor 1, the principal target of Δ9-tetrahydrocannabinol.
David holds a B.S. in Chemistry and an M.S. in Organic Chemistry from the University of Hawaii.
As Co-Founder and President of a Seattle-based software development firm, Jason has worked to provide software solutions for clients in the biotech sector. Jason is also Co-Founder and President of a privately-held company that creates, incubates and commercializes biotech innovations. To date, this work has led to partnerships with some of the largest pharmaceutical companies in the world to commercialize products in the areas of women’s health and autoimmune disease.
Jason is an active angel investor in the biotechnology space, and actively serves on several philanthropic boards in the Greater Seattle area. As the founder of Campamento Esperanza, a summer camp for families with a child facing cancer located in El Salvador, much of Jason’s philanthropic work has been supporting research for pediatric cancer treatment and patients’ mental and emotional wellbeing. For achievements professionally and philanthropically, Jason has been recognized by Inc. Magazine, Puget Sound Business Journal, GeekWire, Seattle Magazine and named an Entrepreneur of the Year finalist by Ernst and Young.
Jason earned his BA in International Business and Marketing from the University of Hawaii, Manoa.